Dror Bashan compensation by year
Protalix BioTherapeutics Summary Compensation Table · all 7 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Salary | $174,725 | $351,569 | $373,817 | $359,972 | $356,929 | $374,108 | $401,836 |
| Bonus | — | $137,522 | $0 | $0 | $892,328 | $0 | $279,491 |
| Stock awards | — | $579,047 | $585,224 | $817,576 | $1,061,558 | $918,318 | $190,015 |
| Option awards | $161,792 | $163,518 | $82,371 | $177,564 | $246,560 | $118,803 | $169,017 |
| Non-equity incentive | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | — |
| All other | $55,082 | $110,296 | $116,287 | $113,184 | $127,566 | $116,563 | $126,575 |
| Total | $391,599 | $1,341,952 | $1,157,699 | $1,468,296 | $2,684,941 | $1,527,792 | $1,166,934 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Protalix BioTherapeutics, Inc. DEF 14A filed April 30, 2026, accession 0001104659-26-053016, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Protalix BioTherapeutics, Inc. filed document, accession 0001104659-26-053016. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 178,750 | $321,750 | — |
| Option | 311,667 | — | $1.64 |
| Option | 140,625 | — | $1.03 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Protalix BioTherapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Protalix BioTherapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Dror Bashan · this page | President and Chief Executive Officer | $1,166,934 |
| Eyal Rubin | Senior Vice President and Chief Financial Officer | $832,461 |
| Yaron Naos | Senior Vice President, Chief Operating Officer | $575,769 |
| Gilad Mamlok | Senior Vice President and Chief Financial Officer | $405,225 |
Board service
Protalix BioTherapeutics board · FY2023–FY2025How this board is paid
Company policy: Protalix BioTherapeutics pays directors a $60,000 cash retainer. As stated in Protalix BioTherapeutics's FY2025 proxy.
The full Protalix BioTherapeutics compensation record
free company briefThis page is one person within Protalix BioTherapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Protalix BioTherapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Protalix BioTherapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Protalix BioTherapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order PLX
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.